During the forecast period, the glioblastoma treatment drugs industry share is anticipated to expand at a 5.7% CAGR. By 2022, the market is projected to be valued US$ 723.30 million, and by 2032, US$ 1,259.13 million. Patients have started getting clinical trials with development agents. Biomarkers are more successful regarding personalized medicine. There is a …